MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii
Raktažodžiai
Santrauka
apibūdinimas
This is a retrospective cohort with collection of tissues samples (FFPE or frozen), including female patients >18-year-old treated in French between 2009 and 2016 for a thyroid carcinoma on struma ovarii. Clinical data and tissues will be centralized for assessment. One of the endpoint is the description of the population (such as baseline clinical and pathologist characteristics, first treatment, survival, treatment relapse) ; the other endpoint is the comparison between the genomic profile of the tumor tissues obtained in NGS and those of the thyroid carcinomas obtained from the TCGA.
Datos
Paskutinį kartą patikrinta: | 06/30/2019 |
Pirmasis pateikimas: | 07/03/2019 |
Numatytas registravimas pateiktas: | 08/08/2019 |
Pirmas paskelbtas: | 08/11/2019 |
Paskutinis atnaujinimas pateiktas: | 08/08/2019 |
Paskutinis atnaujinimas paskelbtas: | 08/11/2019 |
Faktinė studijų pradžios data: | 08/31/2019 |
Numatoma pirminio užbaigimo data: | 11/30/2019 |
Numatoma studijų užbaigimo data: | 04/30/2020 |
Būklė ar liga
Intervencija / gydymas
Other: Retrospective cohort
Fazė
Rankų grupės
Ranka | Intervencija / gydymas |
---|---|
Retrospective cohort Tissue samples | Other: Retrospective cohort Next generation sequencing (NGS) |
Tinkamumo kriterijai
Amžius, tinkami studijuoti | 18 Years Į 18 Years |
Tinkamos studijoms lytys | Female |
Mėginių ėmimo metodas | Non-Probability Sample |
Priima sveikus savanorius | Taip |
Kriterijai | Inclusion Criteria: - Alive patients, - Age > 18 years, - Treatment in France for a TCSO, proven by an histologic diagnosis and registered in the " rare malignant gynecologic tumors " network. Exclusion Criteria: - Patient lost to follow up. |
Rezultatas
Pirminės rezultatų priemonės
1. Treatment description [Between first treatment and last follow up, assessed up to 100 months]
Antrinės rezultatų priemonės
1. Age of diagnostic (years) [At baseline (first treatment)]
2. Comorbidities [At baseline (first treatment)]
3. FIGO stage [At baseline (first treatment)]
4. Histologic type [At baseline (first treatment)]
5. Survival [Between first treatment and last follow up, assessed up to 100 months]
6. Prognostic factors [At baseline (first treatment)]
7. Focus on genes of interest in thyroid carcinomas [At baseline (first treatment)]
8. Focus on ALK translocation [At baseline (first treatment)]
9. Focus on TERT mutation [At baseline (first treatment)]
10. Comparison of the tissue samples genomic profile with the Thyroid carcinoma TCGA genomic profile [At baseline (first treatment)]
11. Comparison between TCSO tissue samples genomic profile and benign SO tissue samples genomic profile [At baseline (first treatment)]